VistaGen Therapeutics (NASDAQ:VTGN) vs. AbbVie (NYSE:ABBV) Head-To-Head Survey

VistaGen Therapeutics (NASDAQ:VTGN) and AbbVie (NYSE:ABBV) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, valuation, institutional ownership, analyst recommendations, earnings and risk.

Risk & Volatility

VistaGen Therapeutics has a beta of 0.39, suggesting that its share price is 61% less volatile than the S&P 500. Comparatively, AbbVie has a beta of 0.29, suggesting that its share price is 71% less volatile than the S&P 500.

Insider and Institutional Ownership

78.4% of VistaGen Therapeutics shares are held by institutional investors. Comparatively, 70.2% of AbbVie shares are held by institutional investors. 2.9% of VistaGen Therapeutics shares are held by insiders. Comparatively, 0.1% of AbbVie shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares VistaGen Therapeutics and AbbVie’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
VistaGen Therapeutics	-2,702.64%	-152.59%	-117.45%
AbbVie	9.80%	-422.07%	14.34%

Valuation and Earnings

This table compares VistaGen Therapeutics and AbbVie”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VistaGen Therapeutics	$1.27 million	8.60	-$69.68 million	($1.66)	-0.15
AbbVie	$61.16 billion	7.53	$4.23 billion	$3.54	73.64

AbbVie has higher revenue and earnings than VistaGen Therapeutics. VistaGen Therapeutics is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings for VistaGen Therapeutics and AbbVie, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VistaGen Therapeutics	1	4	0	0	1.80
AbbVie	0	5	19	2	2.88

VistaGen Therapeutics currently has a consensus price target of $0.95, indicating a potential upside of 285.87%. AbbVie has a consensus price target of $275.95, indicating a potential upside of 5.86%. Given VistaGen Therapeutics’ higher possible upside, equities analysts clearly believe VistaGen Therapeutics is more favorable than AbbVie.

Summary

AbbVie beats VistaGen Therapeutics on 9 of the 15 factors compared between the two stocks.

About VistaGen Therapeutics

Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines. Its product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. In addition, the company is also developing PH15, an early-stage investigational synthetic neuroactive steroid for the treatment of cognition improvement; PH80, an odorless and tasteless synthetic investigational pherine for the treatment of menopausal hot flashes and migraine; PH284, an early-stage investigational synthetic neuroactive steroid for the treatment of wasting syndrome Cachexia; and AV-101, an oral nmdr glycine site antagonist for depression and neurological disorders. Further, it has a license and collaboration agreement with EverInsight Therapeutics Inc. to develop and commercialize to address ophthalmologic and CNS disorders. The company was founded in 1998 and is headquartered in South San Francisco, California.

About AbbVie

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.